Pharmacokinetics of clodronate in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 18, Issue 2, 1998, Pages 204-209

  Saha, Heikki H T ^a,b,d   Ala Houhala, Ilpo O ^b   Liukko Sipi, Sirpa H ^c   Ylitalo, Pauli ^a,b   Pasternack, Amos I ^a,b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c Oy Leiras Finland Ab   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Clodronate; Pharmacokinetics

Indexed keywords

CALCIUM CHANNEL AFFECTING AGENT; CLODRONIC ACID; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CAPILLARY GAS CHROMATOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSATE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG URINE LEVEL; FEMALE; HUMAN; HYPERPARATHYROIDISM; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SKELETON;

EID: 0031922941     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089801800210     Document Type: Article

References (24)

1. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drugs 1991; 42:919-44.
2. Singer FR. Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab 1995; 6:259-88.
3. Russel JE, Termine JD, Avioli LV. Experimental renal osteodystrophy. The response to 25-hydroxycholecalciferol and dichloromethylene diphosphate therapy. J Clin Invest 1975; 56:548-54.
4. Malluche HH. The possible use of bisphosphonates in the treatment of renal osteodystrophy. Clin Nephrol 1992; 38:S87-91.
5. Hamdy NAT, McCloskey EV, Brown CB, Kanis JA. Effects of clodronate in severe hyperparathyroid bone disease in chronic renal failure. Nephron 1990; 56:6-12.
6. Yakatan GJ, Poynor WJ, Talbert RL, Floyd BFF, Slough CL, Ampulski RS, et al. Clodronate kinetics and bio availability. Clin Pharmacol Ther 1982; 31:402-10.
7. Conrad KA, Lee SM. Clodronate kinetics and dynamics. Clin Pharmacol Ther 1981; 30:114-20.
8. Pentikäinen PJ, Elomaa I, Nurmi AK, Kärkkäinen S. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol 1988; 27:222-8.
9. O'Rourke NPO, McCloskey EV, Neugebauer G, Kanis JA. Renal and nonrenal clearance of clodronate in patients with malignancy and renal impairment. Drug Invest 1994; 7:26-33.
10. Saha H, Castren-Kortekangas P, Ojanen S, Juhakoski A, Tuominen J, Tokola O, et al. Pharmacokinetics of clodronate in renal failure. J Bone Miner Res 1994; 9:1953-8.
11. Beigel AE, Rienhoff E, Olbricht CJ. Removal of clodronate by haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant 1995; 10:2266-8.
12. Hené RJ, Visser WJ, Duursma JA, De Bos Kuilt RJ, Dorhout Mees EJ. No effect of APD (amino hydroxy-propylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy. Bone 1990; 11:15-20.
13. Yap AS, Hockings GI, Fleming SJ, Khafagi FA. Use of aminohydroxyproline bisphosphonate (AHPrBP, "APD") for the treatment of hypercalcemia in patients with renal impairment. Clin Nephrol 1990; 34:225-9.
14. Ring T, Sodemann B, Nielsen C, Melsen F, Kornerup HJ. Mineralization defect but no effect on hypercalcemia during clodronate treatment in secondary hyperparathyroidism. Clin Nephrol 1995; 44:209-10.
15. Kanis JA, McCloskey EV. The use of clodronate in disorders of calcium and skeletal metabolism. In: Kanis JA, ed. Calcium metabolism. (Progress in Basic and Clinical Pharmacology, Vol. 4.) Basel: S. Karger, 1990:89-136.
16. Hanhijàrvi H, Elomaa I, Karlsson M, Lauren L. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days. Int J Clin Pharmacol Ther Toxicol 1989; 27:602-6.
17. Mönkkönen J, Urtti A, Paronen P, Elo HA, Ylitalo P. The uptake of clodronate (dichloromethylene bisphosphatate) by macrophages in vivo and in vitro. Drug Metab Dispos 1989; 17:690-3.
18. Powell JH, DeMark BR. Clinical pharmacokinetics of diphosphonates. In: Garattini S, ed. Bone resorption, metastases and diphosphonates. New York: Raven Press, 1985:41-9.
19. Fogelman I, Smith L, Mazess R, Wilson MA, Bevan JA. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 1986; 24:57-62.
20. Delmez JA, Slatopolsky E. Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19:303-17.
21. Schaefer K. Unsatisfactory control of serum phosphate: Why is it so common and what can be done? Nephrol Dial Transplant 1994; 9:1366-7.
22. Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, et al. Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res 1996; 11:178-82.
23. Queries LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75:145-50.
24. Hutchison AJ, Whitehouse RW, Freemont AJ, Adams JE, Mawer EB, Gokal R. Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis. Am J Nephrol 1994; 14:19-29.